title: Statin therapy--Part II: Clinical considerations for cardiovascular disease.
abstract: 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are the medical treatment of choice for hypercholesterolemia. In addition to achieving a therapeutic decrease in serum cholesterol levels, statin therapy appears to promote pleiotropic effects that are independent of changes in serum cholesterol. These cholesterol lowering and pleiotropic effects are beneficial not only for the coronary circulation, but for the myocardium and peripheral arterial system as well. Patients receiving statin therapy must be carefully monitored, however, as statins potentially have harmful side effects and drug interactions. This article is part II of a 2-part review, and it focuses on the clinical aspects of statin therapy in cardiovascular disease.
authors.affiliation: Division of Vascular Surgery and Endovascular Services, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Sadowitz
authors.forename: Keri
authors.initials: K
authors.lastname: Seymour
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Costanza
authors.forename: Vivian
authors.initials: V
authors.lastname: Gahtan
mesh_terms: D001018:Aortic Diseases / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D003324:Coronary Artery Disease / Q000188:drug therapy; D004347:Drug Interactions; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D058729:Peripheral Arterial Disease / Q000188:drug therapy; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors